Fundamental Analysis of Meiya Optoelectronics: Driven by AI and Equipment, Strong Growth Momentum

In today’s era of deep integration of technology and manufacturing, Meiya Optoelectronics (002690), as a leading enterprise in the domestic color sorting machine and high-end medical imaging equipment fields, is demonstrating strong development potential and investment value through AI empowerment and innovation-driven strategies.

Founded in 2000, Meiya Optoelectronics is a high-tech enterprise focused on the research, development, production, and sales of optoelectronic detection and grading equipment and its application software. The company’s main products include color sorting machines, X-ray detection equipment, and high-end medical imaging devices, widely used in food safety, healthcare, and industrial product inspection.

1. Steady Growth in Financial Performance

1. Impressive Performance in the First Half of 2025

According to the 2025 semi-annual report, Meiya Optoelectronics achieved operating revenue of 1.023 billion yuan, a year-on-year increase of 9.92%; net profit attributable to shareholders was 303 million yuan, a year-on-year increase of 11.34%; and net profit excluding non-recurring items was 295 million yuan, a year-on-year increase of 11.62%.

Notably, the second quarter performance was particularly outstanding: quarterly revenue reached 630 million yuan, a year-on-year increase of 5.24%; net profit attributable to shareholders was 194 million yuan, a year-on-year increase of 13.62%. This indicates a continuous enhancement in the company’s profitability.

2. Continuous Improvement in Profitability

In the first half of 2025, the company’s gross profit margin was **52.14%**, an increase of 1.26 percentage points year-on-year; the net profit margin was **29.61%**, an increase of 0.38 percentage points year-on-year. The improvement in gross margin is mainly attributed to the automation upgrades in smart factories, which reduced labor costs and increased production efficiency.

3. Significant Improvement in Cash Flow

The net cash flow generated from operating activities was 393 million yuan, a year-on-year increase of **125.28%**. The substantial improvement in cash flow is primarily due to the company’s strengthened collection of sales receivables, optimized sales channels, maintained healthy inventory levels, and enhanced cost control capabilities.

4. Enhanced Operational Capability

Financial Indicator	First Half of 2025	Year-on-Year Change
Inventory Turnover Days	121.05 days	Decreased by 50.66 days
Accounts Receivable Turnover Days	77.97 days	Decreased by 31.45 days

These indicators demonstrate a significant improvement in the company’s operational efficiency.

2. Core Business Analysis

1. Color Sorting Machine Business: Stable Growth, AI-Driven Innovation

The color sorting machine is Meiya Optoelectronics’ traditional advantage business, achieving revenue of 742 million yuan in the first half of 2025, a year-on-year increase of 15.17%, accounting for 72.5% of total revenue.

Technological Innovation: The company launched the new generation AI + Intelligent Color Sorting Machine Meiya Master 4.0. This product relies on the company’s self-developed AI sorting model, integrating a multi-modal general artificial intelligence engine and a collaborative network of collective intelligence, injecting intelligent decision-making capabilities into the production line.
Solution Upgrades: The company released a “full-stack intelligent rice processing solution” that achieves digital and intelligent management of the entire process from raw grain storage to rice milling, color sorting, and packaging, which has been implemented in several benchmark projects worldwide.
Market Performance:

The domestic market remains highly prosperous, with revenue reaching 511 million yuan, a year-on-year increase of 19.20%
The overseas market continues to grow despite objective constraints, with revenue of 231 million yuan, a year-on-year increase of 7.17%

2. Medical Equipment Business: Stabilizing Recovery, Promising Future Development

In the first half of 2025, medical equipment revenue was 204 million yuan, remaining basically flat year-on-year, with a gross margin of 48.45%. The company effectively curbed the significant decline in medical revenue since 2024 through continuous investment in technology and product upgrades and marketing.

Diverse Product Line: The company’s high-end medical imaging equipment product line includes:

Oral X-ray CT diagnostic machine (oral CBCT)
Oral digital impression device (intraoral scanner)
ENT CT
Mobile head CT
Orthopedic surgical navigation equipment

Technological Innovation: The company launched the industry’s first oral imaging intelligent device “Meiya Imaging Engine”, breaking through the traditional attributes of oral CBCT tools, constructing a “hardware + software + ecosystem” integrated intelligent diagnosis and treatment system.
Platform Development: As of the end of June 2025, the “Meiya Dental” oral health digital cloud platform has surpassed 10,000 end users, laying a solid foundation for the sustained and stable development of future medical business.
New Product Approval: The company’s self-developed endoscope camera light source integrated machine obtained medical device registration certification in April 2025, further enriching the medical imaging product line.

3. R&D Innovation and Technical Reserves

Meiya Optoelectronics continues to strengthen R&D investment, with R&D expenditure in the first half of 2025 amounting to 70.013 million yuan, a year-on-year increase of 19.32%, accounting for 6.85% of operating revenue.

As of the end of June 2025, the company holds:

Effective authorized invention patents: 175 (including 3 foreign authorized invention patents)
Utility model patents: 205
Design patents: 51

With high-intensity R&D investment, the company has continuously launched new products across various business segments, effectively enhancing product market competitiveness.

4. Institutional Perspectives and Valuation Analysis

1. Institutional Ratings and Profit Forecasts

Zhontai Securities maintains a “Buy” rating, forecasting the company’s net profit attributable to shareholders for 2025-2027 as follows:

2025: 759 million yuan (year-on-year increase of 16.85%)
2026: 888 million yuan (year-on-year increase of 17.11%)
2027: 1.022 billion yuan (year-on-year increase of 15.00%)

Based on the stock price on August 25, 2025, the corresponding PE ratios are 20.2, 17.2, and 15.0.

China Post Securities gives a “Hold” rating, forecasting the company’s net profit attributable to shareholders for 2025-2027 as follows:

2025: 722 million yuan (year-on-year increase of 11.18%)
2026: 813 million yuan (year-on-year increase of 12.61%)
2027: 909 million yuan (year-on-year increase of 11.80%)

2. Summary of Institutional Target Prices

Brokerage Institution	Rating	Target Price (Yuan)
Average of 6 institutions in the last 6 months	–	19.00
Highest Target Price	–	20.00
Lowest Target Price	–	18.00

3. Valuation Level Analysis

The company’s current valuation is within a relatively reasonable range:

According to Zhontai Securities’ forecast, the PE for 2025 is 20.2 times
According to China Post Securities’ forecast, the PE for 2025 is 24.23 times

Compared to the industry average, the company’s valuation is slightly higher than the average level of the specialized equipment industry, but considering the company’s leading position in the color sorting machine field and the growth potential of medical equipment, this valuation is reasonable.

5. Risk Factor Analysis

Industry Risk: The development of the food testing industry may not meet expectations; the domestic oral CBCT industry may not develop as anticipated.
Market Risk: The development of overseas business may not meet expectations; there is a risk of intensified competition in the domestic oral CBCT market.
Technical Risk: The development of chairside restoration systems may not meet expectations.
Financial Risk: Uncertainty in the impact of exchange gains and losses on the company’s performance; uncertainty in the impact of other operating income on the company’s performance.
Stock Price Risk: According to technical analysis, the stock price is approaching a key resistance level, requiring caution against potential pullback risks.

6. Investment Recommendations and Operational Strategies

1. Long-term Investment Value

Meiya Optoelectronics has significant long-term investment value: the demand for color sorting machines is rigid, the oral sector has long-term growth attributes, and the company is accelerating overseas expansion, which provides a certainty premium. The company’s fundamentals are positive, driven by AI and equipment, with strong growth momentum.

2. Operational Suggestions

For conservative investors: It is recommended to adopt a phased investment strategy, considering initial positions near the current price level, and adding positions every 5%-8% decline for medium to long-term holding.
For aggressive investors: Consider following up after the stock price breaks through key resistance levels (e.g., 16.05 yuan), with target prices referencing the institutional average forecast range of 19-20 yuan.
Precautions: Given the recent overall market volatility, it is essential to control positions and avoid excessive concentration in investments. Closely monitor the company’s quarterly reports and business progress, especially the recovery of the medical equipment business and the expansion of overseas markets.

3. Investment Cycle Recommendations

Short-term (1-6 months): Focus on technical breakthroughs and changes in market sentiment to seize opportunities amid volatility.
Medium-term (6-12 months): Track the company’s performance achievements, particularly the recovery progress of the medical equipment business and the market promotion effects of new products.
Long-term (over 1 year): Optimistic about the company’s continuous innovation capabilities and market expansion in the AI + equipment field, with stable growth in the color sorting machine business providing a safety margin and the medical equipment business expected to contribute incremental revenue.

Conclusion

Meiya Optoelectronics (002690) has a solid fundamental outlook, steady performance growth, AI innovation empowering traditional businesses, and the medical equipment business is expected to recover upward. The company is financially healthy, with significant improvements in cash flow and enhanced operational capabilities.

Considering institutional ratings and target prices, the company’s current valuation is within a reasonable range. Investors can adopt corresponding operational strategies based on their risk preferences and investment styles, while being cautious of market risks and industry competition risks.

Disclaimer: This article is for reference only and does not constitute any investment advice. Investment involves risks, and market entry should be approached with caution. Investors should independently assess their situations and bear investment risks.